AP1917A - Azaindoles - Google Patents

Azaindoles

Info

Publication number
AP1917A
AP1917A AP2006003492A AP2006003492A AP1917A AP 1917 A AP1917 A AP 1917A AP 2006003492 A AP2006003492 A AP 2006003492A AP 2006003492 A AP2006003492 A AP 2006003492A AP 1917 A AP1917 A AP 1917A
Authority
AP
ARIPO
Prior art keywords
azaindoles
Prior art date
Application number
AP2006003492A
Other languages
English (en)
Other versions
AP2006003492A0 (en
Inventor
Paul Joseph Cox
Tahir Nadeem Majid
Chris Edlin
Original Assignee
Aventis Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9930698.7A external-priority patent/GB9930698D0/en
Application filed by Aventis Pharma Ltd filed Critical Aventis Pharma Ltd
Publication of AP2006003492A0 publication Critical patent/AP2006003492A0/xx
Application granted granted Critical
Publication of AP1917A publication Critical patent/AP1917A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Transplantation (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
AP2006003492A 1999-12-24 2000-12-27 Azaindoles AP1917A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9930698.7A GB9930698D0 (en) 1999-12-24 1999-12-24 Chemical compounds
US21581800P 2000-07-05 2000-07-05
PCT/GB2000/004993 WO2001047922A2 (fr) 1999-12-24 2000-12-27 Azaindoles

Publications (2)

Publication Number Publication Date
AP2006003492A0 AP2006003492A0 (en) 2006-02-28
AP1917A true AP1917A (en) 2008-11-12

Family

ID=26316153

Family Applications (2)

Application Number Title Priority Date Filing Date
AP2006003492A AP1917A (en) 1999-12-24 2000-12-27 Azaindoles
APAP/P/2002/002516A AP1587A (en) 1999-12-24 2000-12-27 Azaindoles.

Family Applications After (1)

Application Number Title Priority Date Filing Date
APAP/P/2002/002516A AP1587A (en) 1999-12-24 2000-12-27 Azaindoles.

Country Status (27)

Country Link
US (2) US6770643B2 (fr)
EP (2) EP1990343B1 (fr)
JP (1) JP5436507B2 (fr)
KR (2) KR100910488B1 (fr)
CN (2) CN1615873A (fr)
AP (2) AP1917A (fr)
AU (1) AU777717B2 (fr)
BG (2) BG66066B1 (fr)
BR (1) BR0017038A (fr)
CA (2) CA2699568C (fr)
CY (1) CY1110951T1 (fr)
CZ (2) CZ301751B6 (fr)
DZ (1) DZ3377A1 (fr)
EA (1) EA005212B1 (fr)
EE (1) EE05180B1 (fr)
HK (1) HK1050191B (fr)
HR (1) HRP20020547B1 (fr)
HU (1) HUP0203895A3 (fr)
IL (3) IL150388A0 (fr)
MA (1) MA26857A1 (fr)
MX (1) MXPA02006338A (fr)
NO (2) NO323766B1 (fr)
NZ (1) NZ519121A (fr)
OA (1) OA12514A (fr)
PL (1) PL209572B1 (fr)
SK (2) SK288019B6 (fr)
WO (1) WO2001047922A2 (fr)

Families Citing this family (137)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
OA12514A (en) 1999-12-24 2006-05-29 Aventis Pharma Ltd Azaindoles.
JP4328527B2 (ja) * 2001-02-02 2009-09-09 ブリストル−マイヤーズ スクイブ カンパニー 置換アザインドールオキソアセチックピペラジン誘導体の組成物と抗ウイルス活性
GB0108770D0 (en) 2001-04-06 2001-05-30 Eisai London Res Lab Ltd Inhibitors
GB0115109D0 (en) 2001-06-21 2001-08-15 Aventis Pharma Ltd Chemical compounds
WO2003000690A1 (fr) * 2001-06-25 2003-01-03 Aventis Pharmaceuticals Inc. Synthese de composes heterocycliques faisant appel a une technologie micro-onde
EP2335700A1 (fr) 2001-07-25 2011-06-22 Boehringer Ingelheim (Canada) Ltd. Inhibiteurs de la polymerase du virus hepatitis C avec une structure heterobicylic
US20030158195A1 (en) 2001-12-21 2003-08-21 Cywin Charles L. 1,6 naphthyridines useful as inhibitors of SYK kinase
US6884889B2 (en) * 2002-03-25 2005-04-26 Bristol-Myers Squibb Co. Processes for the preparation of antiviral 7-azaindole derivatives
CA2480317A1 (fr) 2002-03-28 2003-10-09 Eisai Co., Ltd. 7-azaindoles en tant qu'inhibiteurs de kinases a terminaison c-jun n pour le traitement de troubles neurodegeneratifs
EP1490365B1 (fr) * 2002-03-28 2010-02-10 Eisai R&D Management Co., Ltd. Azaindoles en tant qu'inhibiteurs de kinases a terminaison c-jun n
US20050124620A1 (en) * 2002-04-09 2005-06-09 Martyn Frederickson Pharmaceutical compounds
EP1495016A2 (fr) * 2002-04-09 2005-01-12 Astex Technology Limited Composes heterocycliques et leur utilisation comme modulateurs de la kinase p38 map
TW200307542A (en) * 2002-05-30 2003-12-16 Astrazeneca Ab Novel compounds
SE0201635D0 (sv) 2002-05-30 2002-05-30 Astrazeneca Ab Novel compounds
SE0202241D0 (sv) 2002-07-17 2002-07-17 Astrazeneca Ab Novel Compounds
EP1388541A1 (fr) * 2002-08-09 2004-02-11 Centre National De La Recherche Scientifique (Cnrs) Pyrrolopyrazines utilisées comme inhibiteurs de kinases
US7186716B2 (en) 2002-08-12 2007-03-06 Sugen, Inc. 3-Pyrrol-pyridopyrazoles and 3-pyrrolyl-indazoles as novel kinase inhibitors
SE0202464D0 (sv) * 2002-08-14 2002-08-14 Astrazeneca Ab Use of compounds
WO2004063181A1 (fr) * 2003-01-03 2004-07-29 Genzyme Corporation Derives d'uree et leur utilisation comme agents anti-inflammatoires
US7098231B2 (en) * 2003-01-22 2006-08-29 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
US7223785B2 (en) 2003-01-22 2007-05-29 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
GB0305142D0 (en) 2003-03-06 2003-04-09 Eisai London Res Lab Ltd Synthesis
EP1599475A2 (fr) * 2003-03-06 2005-11-30 Eisai Co., Ltd. Inhibiteurs des jun-kinases (jnk)
SE0300908D0 (sv) 2003-03-31 2003-03-31 Astrazeneca Ab Azaindole derivatives, preparations thereof, uses thereof and compositions containing them
SE0301372D0 (sv) * 2003-05-09 2003-05-09 Astrazeneca Ab Novel compounds
US7612086B2 (en) 2003-05-16 2009-11-03 Eisai R & D Management Co. Ltd. JNK inhibitors
SE0301569D0 (sv) 2003-05-27 2003-05-27 Astrazeneca Ab Novel compounds
KR101415503B1 (ko) 2003-07-17 2014-07-04 플렉시콘, 인코퍼레이티드 Ｐｐａｒ 활성 화합물
SE0302232D0 (sv) 2003-08-18 2003-08-18 Astrazeneca Ab Novel Compounds
SE0303180D0 (sv) * 2003-11-26 2003-11-26 Astrazeneca Ab Novel compounds
EP1694686A1 (fr) * 2003-12-19 2006-08-30 Takeda San Diego, Inc. Inhibiteurs de kinase
PT1718608E (pt) * 2004-02-20 2013-08-01 Boehringer Ingelheim Int Inibidores da polimerase viral
FR2868422B1 (fr) 2004-03-31 2006-07-14 Aventis Pharma Sa Nouveaux derives pyrrolo(2,3-b) pyridine, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
EP1763524A1 (fr) * 2004-04-23 2007-03-21 Takeda San Diego, Inc. Derives d'indole et leur utilisation en tant qu'inhibiteurs de kinases
EP1778669A2 (fr) * 2004-08-18 2007-05-02 Takeda San Diego, Inc. Inhibiteurs de kinase
FR2876103B1 (fr) 2004-10-01 2008-02-22 Aventis Pharma Sa Nouveaux derives bis-azaindoles, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
EP1812439B2 (fr) 2004-10-15 2017-12-06 Takeda Pharmaceutical Company Limited Inhibiteurs de kinase
AR054416A1 (es) 2004-12-22 2007-06-27 Incyte Corp Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas.
WO2006066913A2 (fr) * 2004-12-23 2006-06-29 F. Hoffmann-La Roche Ag Derives benzamides, leur fabrication et leur utilisation comme agents pharmaceutiques
WO2006066914A2 (fr) * 2004-12-23 2006-06-29 F. Hoffmann-La Roche Ag Derives carbamates heterocycliques, leur fabrication et leur utilisation comme agents pharmaceutiques
GB0500604D0 (en) 2005-01-13 2005-02-16 Astrazeneca Ab Novel process
US20060183758A1 (en) * 2005-02-17 2006-08-17 Cb Research And Development, Inc. Method for synthesis of AZA-annelated pyrroles, thiophenes, and furans
CA2609126A1 (fr) 2005-05-20 2006-11-30 Vertex Pharmaceuticals Incorporated Pyrrolopyridines utiles en tant qu'inhibiteurs de proteines kinases
CN102127078A (zh) * 2005-07-14 2011-07-20 安斯泰来制药株式会社 Janus激酶3的杂环类抑制剂
KR20080026654A (ko) * 2005-07-14 2008-03-25 아스텔라스세이야쿠 가부시키가이샤 헤테로시클릭 야누스 키나제 3 억제제
GB0516156D0 (en) 2005-08-05 2005-09-14 Eisai London Res Lab Ltd JNK inhibitors
US8076365B2 (en) * 2005-08-12 2011-12-13 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
CA2621261C (fr) * 2005-09-22 2014-05-20 Incyte Corporation Inhibiteurs tetracycliques de janus kinases
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
WO2007067537A1 (fr) * 2005-12-07 2007-06-14 Osi Pharmaceuticals, Inc. Composés inhibant les pyrrolopyridine kinases
SI2348023T1 (sl) * 2005-12-13 2015-10-30 Incyte Corporation S heteroarilom substituirani pirolo (2,3-b)piridini in pirolo (2,3-b)pirimidini kot zaviralci janus kinaze
PT1962830E (pt) * 2005-12-23 2013-05-29 Glaxosmithkline Llc Inibidores azaindólicos de cinases aurora
US20070208053A1 (en) * 2006-01-19 2007-09-06 Arnold Lee D Fused heterobicyclic kinase inhibitors
CA2651732C (fr) * 2006-05-18 2014-10-14 Mannkind Corporation Inhibiteurs de kinases intracellulaires
WO2007138282A2 (fr) 2006-05-26 2007-12-06 Astrazeneca Ab Nouveaux composés
WO2008014249A2 (fr) * 2006-07-24 2008-01-31 Sanofi-Aventis Préparation améliorée de composés d'azaindole
GB0617161D0 (en) * 2006-08-31 2006-10-11 Vernalis R&D Ltd Enzyme inhibitors
CL2007002617A1 (es) * 2006-09-11 2008-05-16 Sanofi Aventis Compuestos derivados de pirrolo[2,3-b]pirazin-6-ilo; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar inflamacion de las articulaciones, artritis reumatoide, tumores, linfoma de las celulas del manto.
EP2223925A1 (fr) * 2006-10-09 2010-09-01 Takeda Pharmaceutical Company Limited Inhibiteurs de kinase
MX2009003793A (es) 2006-10-09 2009-12-14 Takeda Pharmaceutical Inhibidores de cinasa.
JP5492565B2 (ja) * 2006-12-22 2014-05-14 インサイト・コーポレイション Ｊａｎｕｓキナーゼ阻害剤としての置換複素環
CL2008001709A1 (es) 2007-06-13 2008-11-03 Incyte Corp Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras.
CU24179B1 (es) * 2007-06-13 2016-04-25 Incyte Corp SALES DE ÁCIDO MALEICO Y DE ÁCIDO SULFÚRICO DE (R)-3-(4-(7H-PIRROLO[2,3-d]PIRIMIDIN-4-IL)-1H-PIRAZOL-1-IL)-3-CICLOPENTILPROPANITRILO
BRPI0820544A2 (pt) * 2007-11-16 2015-06-16 Incyte Corp 4-pirazolil-n-arilpirimidin-2-aminas e pirazolil-n-heteroarilpirimidin-2-aminas como inibidores de janus cinase
WO2009106442A1 (fr) 2008-02-25 2009-09-03 F. Hoffmann-La Roche Ag Inhibiteurs de la pyrrolopyrazine kinase
CN101945877B (zh) 2008-02-25 2013-07-03 霍夫曼-拉罗奇有限公司 吡咯并吡嗪激酶抑制剂
JP5368484B2 (ja) * 2008-02-25 2013-12-18 エフ．ホフマン−ラ ロシュ アーゲー ピロロピラジンキナーゼ阻害剤
ATE522536T1 (de) 2008-02-25 2011-09-15 Hoffmann La Roche Pyrrolopyrazin-kinasehemmer
ATE519763T1 (de) 2008-02-25 2011-08-15 Hoffmann La Roche Pyrrolopyrazin-kinasehemmer
BRPI0909659A2 (pt) * 2008-03-10 2015-09-22 Sanofi Aventis tratamento para distúrbios relacionados oculares
BRPI0909040B8 (pt) 2008-03-11 2021-05-25 Incyte Holdings Corp derivados de azetidina e ciclobutano, seus usos, e composição
US8871753B2 (en) * 2008-04-24 2014-10-28 Incyte Corporation Macrocyclic compounds and their use as kinase inhibitors
CL2009001884A1 (es) * 2008-10-02 2010-05-14 Incyte Holdings Corp Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco.
WO2010046215A2 (fr) * 2008-10-21 2010-04-29 Syngenta Participations Ag Dérivés de diazaindole et leur emploi en tant que fongicides
WO2010085597A1 (fr) 2009-01-23 2010-07-29 Incyte Corporation Composés macrocycliques et leur utilisation en tant qu'inhibiteurs des kinases
US20110112101A1 (en) * 2009-03-05 2011-05-12 Sanofi-Aventis Treatment for ocular-related disorders
AR075869A1 (es) * 2009-03-19 2011-05-04 Sanofi Aventis Sintesis de azaindoles
US8716303B2 (en) * 2009-05-22 2014-05-06 Incyte Corporation N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
HUE046493T2 (hu) 2009-05-22 2020-03-30 Incyte Holdings Corp 3-[4-(7H-Pirrolo[2,3-d]pirimidin-4-il)-lH-pirazol-l-il]oktán- vagy heptán-nitril JAK inhibitorokként
EP2454262B1 (fr) * 2009-07-15 2014-05-14 Abbott Laboratories Inhibiteurs des pyrrolopyrazines kinases
CA2771939A1 (fr) 2009-08-26 2011-03-03 Nycomed Gmbh Methylpyrrolopyrimidine-carboxamides
TW201113285A (en) * 2009-09-01 2011-04-16 Incyte Corp Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
PT2486041E (pt) 2009-10-09 2013-11-14 Incyte Corp Derivados hidroxilo, ceto e glucuronido de 3-(4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)-3-ciclopentil-propanonitrilo
EP2338890A1 (fr) 2009-12-22 2011-06-29 Bayer CropScience AG Dérivés de 4,7-diazaindole et leur utilisation en tant que fongicides
JP5858434B2 (ja) * 2010-02-18 2016-02-10 インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ Ｊａｎｕｓキナーゼ阻害薬としてのシクロブタンおよびメチルシクロブタン誘導体
WO2011109932A1 (fr) * 2010-03-09 2011-09-15 F.Hoffmann-La Roche Ag Nouveau procédé pour la fabrication de 7-azaindoles 5-halogénés
DK3050882T3 (en) * 2010-03-10 2018-03-19 Incyte Holdings Corp PIPERIDIN-4-YL-AZETIDINE DERIVATIVES AS JAK1 INHIBITORS
US8518945B2 (en) 2010-03-22 2013-08-27 Hoffmann-La Roche Inc. Pyrrolopyrazine kinase inhibitors
US8481541B2 (en) 2010-03-22 2013-07-09 Hoffmann-La Roche Inc. Pyrrolopyrazine kinase inhibitors
JP2013526558A (ja) 2010-05-20 2013-06-24 エフ．ホフマン−ラ ロシュ アーゲー Ｓｙｋ及びｊａｋ阻害剤としてのピロロピラジン誘導体
ME02445B (fr) 2010-05-21 2016-09-20 Incyte Holdings Corp Formulation topique pour inhibiteur de jak
UA113156C2 (xx) 2010-11-19 2016-12-26 Циклобутилзаміщені похідні піролопіридину й піролопіримідину як інгібітори jak
JP5917544B2 (ja) 2010-11-19 2016-05-18 インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ Ｊａｋ阻害剤としての複素環置換ピロロピリジンおよびピロロピリミジン
JP5936628B2 (ja) 2011-02-18 2016-06-22 ノバルティス・ファルマ・アクチェンゲゼルシャフトＮｏｖａｒｔｉｓ Ｐｈａｒｍａ ＡＧ ｍＴＯＲ／ＪＡＫ阻害剤併用療法
CA2834604A1 (fr) 2011-05-10 2012-11-15 Merck Sharp & Dohme Corp. Aminopyrimidines en tant qu'inhibiteurs de syk
AU2012253886A1 (en) 2011-05-10 2013-10-31 Merck Sharp & Dohme Corp. Pyridyl aminopyridines as Syk inhibitors
US9145391B2 (en) 2011-05-10 2015-09-29 Merck Sharp & Dohme Corp. Bipyridylaminopyridines as Syk inhibitors
US8691807B2 (en) 2011-06-20 2014-04-08 Incyte Corporation Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors
WO2013023119A1 (fr) 2011-08-10 2013-02-14 Novartis Pharma Ag Polythérapie par jak p13k/mtor
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
DE102011111400A1 (de) * 2011-08-23 2013-02-28 Merck Patent Gmbh Bicyclische heteroaromatische Verbindungen
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
US9006444B2 (en) 2011-10-05 2015-04-14 Merck Sharp & Dohme Corp. Phenyl carboxamide-containing spleen tyrosine kinase (SYK) inhibitors
WO2013052394A1 (fr) 2011-10-05 2013-04-11 Merck Sharp & Dohme Corp. Inhibiteurs de tyrosine kinase de la rate (syk) contenant un 2-pyridyl carboxamide
EP2763975B1 (fr) 2011-10-05 2016-04-06 Merck Sharp & Dohme Corp. Inhibiteurs de tyrosine kinase de la rate (syk) contenant un 3-pyridyl carboxamide
CN104114558B (zh) * 2012-02-21 2016-10-26 默克专利股份公司 呋喃并吡啶衍生物
TW201406761A (zh) 2012-05-18 2014-02-16 Incyte Corp 做爲ｊａｋ抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物
EP2863913B1 (fr) 2012-06-20 2018-09-12 Merck Sharp & Dohme Corp. Analogues d'imidazolyle en tant qu'inhibiteurs de syk
WO2013192125A1 (fr) 2012-06-20 2013-12-27 Merck Sharp & Dohme Corp. Dérivés de pyrazolyle en tant qu'inhibiteurs de syk
US9376418B2 (en) 2012-06-22 2016-06-28 Merck Sharp & Dohme Corp. Substituted pyridine spleen tyrosine kinase (SYK) inhibitors
WO2013192088A1 (fr) 2012-06-22 2013-12-27 Merck Sharp & Dohme Corp. Inhibiteurs de tyrosine kinase splénique (syk) diazines et triazines substituées
PT2877467T (pt) 2012-07-26 2017-01-02 Glaxo Group Ltd 2-(azaindol-2-il)benzimidazóis como inibidores de pad4
EP2884982B1 (fr) 2012-08-20 2017-09-20 Merck Sharp & Dohme Corp. Inhibiteurs de la phényle tyrosine kinase de la rate (syk) substitués
US9586931B2 (en) 2012-09-28 2017-03-07 Merck Sharp & Dohme Corp. Triazolyl derivatives as Syk inhibitors
PE20151157A1 (es) 2012-11-15 2015-08-19 Incyte Corp Formas de dosificacion de ruxolitinib de liberacion sostenida
PE20151902A1 (es) 2013-03-06 2015-12-26 Incyte Corp Proceso e intermedios para hacer un inhibidor de jak
UY35419A (es) * 2013-03-14 2014-10-31 Abbvie Inc Inhibidores de cdk9 quinasa de pirrolo (2,3- b) piridina
BR112015023187A2 (pt) * 2013-03-14 2017-07-18 Abbvie Inc inibidores de pirrolo[2,3 - b] piridina cdk9 kinase
US20140303121A1 (en) 2013-03-15 2014-10-09 Plexxikon Inc. Heterocyclic compounds and uses thereof
TWI634111B (zh) 2013-03-15 2018-09-01 普雷辛肯公司 雜環化合物及其用途
RS60469B1 (sr) 2013-08-07 2020-07-31 Incyte Corp Dozni oblici sa produženim oslobađanjem za jak1 inhibitor
US9498467B2 (en) 2014-05-30 2016-11-22 Incyte Corporation Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1
TWI618704B (zh) 2014-12-11 2018-03-21 貝達醫藥公司 作為ｅｇｆｒ調節劑之經取代之２－苯胺嘧啶衍生物
CA3007462C (fr) 2015-12-07 2023-10-24 Plexxikon Inc. Composes et procedes pour la modulation de kinase, et indications associees
US20190060286A1 (en) 2016-02-29 2019-02-28 University Of Florida Research Foundation, Incorpo Chemotherapeutic Methods
US20200071326A1 (en) * 2017-04-14 2020-03-05 Syros Pharmaceuticals, Inc. Tam kinase inhibitors
US10428067B2 (en) 2017-06-07 2019-10-01 Plexxikon Inc. Compounds and methods for kinase modulation
US10717735B2 (en) 2017-10-13 2020-07-21 Plexxikon Inc. Solid forms of a compound for modulating kinases
WO2019113487A1 (fr) 2017-12-08 2019-06-13 Incyte Corporation Polythérapie à faible dose pour le traitement de néoplasmes myéloprolifératifs
MA51771B1 (fr) 2018-01-30 2022-03-31 Incyte Corp Procédés de préparation de (1-(3-fluoro-2-(trifluorométhyl)isonicotinyl)pipéridine-4-one)
CN112423759A (zh) 2018-03-30 2021-02-26 因赛特公司 使用jak抑制剂治疗化脓性汗腺炎
AR117472A1 (es) 2018-12-21 2021-08-11 Celgene Corp Inhibidores de tienopiridina de ripk2
CN114364798A (zh) 2019-03-21 2022-04-15 欧恩科斯欧公司 用于治疗癌症的Dbait分子与激酶抑制剂的组合
US20220401436A1 (en) 2019-11-08 2022-12-22 INSERM (Institute National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021102258A1 (fr) 2019-11-22 2021-05-27 Incyte Corporation Polythérapie comprenant un inhibiteur d'alk2 et un inhibiteur de jak2
WO2021148581A1 (fr) 2020-01-22 2021-07-29 Onxeo Nouvelle molécule dbait et son utilisation
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0737685A1 (fr) * 1995-04-14 1996-10-16 Adir Et Compagnie Nouveaux composés pyridiniques, leurs procédés de préparation et les compositions pharmaceutiques qui les contiennent
WO1998022457A1 (fr) * 1996-11-19 1998-05-28 Amgen Inc. Agents anti-inflammatoires a base de pyrrole condense a substitution aryle et heteroaryle
WO1998047889A1 (fr) * 1997-04-23 1998-10-29 Novartis Ag Derives de chromane
WO1999020624A1 (fr) * 1997-10-20 1999-04-29 F.Hoffmann-La Roche Ag Inhibiteurs bicycliques d'une kinase

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB966264A (en) 1961-08-31 1964-08-06 Distillers Co Yeast Ltd Production of alkyl pyridines
GB1141949A (en) * 1966-02-23 1969-02-05 Sterling Drug Inc 7-azaindole derivatives
US3992392A (en) * 1973-04-27 1976-11-16 The Ohio State University Research Foundation Synthesis of indoles from anilines and intermediates therein
EP0405602A1 (fr) 1989-06-30 1991-01-02 Laboratorios Vinas S.A. Dérivés zinciques de substances antiiflammatoires doués d'une activité thérapeutique améliorée
US5202108A (en) * 1990-10-12 1993-04-13 Analytical Development Corporation Process for producing ferrate employing beta-ferric oxide
SE9100920D0 (sv) 1991-03-27 1991-03-27 Astra Ab New active compounds
FR2687402B1 (fr) 1992-02-14 1995-06-30 Lipha Nouveaux azaindoles, procedes de preparation et medicaments les contenant.
JP3119758B2 (ja) 1993-02-24 2000-12-25 日清製粉株式会社 ７−アザインドール誘導体及びこれを有効成分とする抗潰瘍薬
US6756388B1 (en) 1993-10-12 2004-06-29 Pfizer Inc. Benzothiophenes and related compounds as estrogen agonists
EP0763035A4 (fr) * 1994-06-09 1997-10-01 Smithkline Beecham Corp Antagonistes du recepteur de l'endotheline
US5521213A (en) 1994-08-29 1996-05-28 Merck Frosst Canada, Inc. Diaryl bicyclic heterocycles as inhibitors of cyclooxygenase-2
US5589482A (en) 1994-12-14 1996-12-31 Pfizer Inc. Benzo-thiophene estrogen agonists to treat prostatic hyperplasia
GB2298199A (en) 1995-02-21 1996-08-28 Merck Sharp & Dohme Synthesis of azaindoles
AR004010A1 (es) 1995-10-11 1998-09-30 Glaxo Group Ltd Compuestos heterociclicos
ID19430A (id) 1996-07-13 1998-07-09 Glaxo Group Ltd Senyawa senyawa heterosiklik
WO1998006703A1 (fr) 1996-08-14 1998-02-19 Warner-Lambert Company Derives 2-phenyle benzimidazole en tant qu'antagonistes de mcp-1
US5783969A (en) 1996-09-04 1998-07-21 Motorola, Inc. Method and system for preventing an amplifier overload condition in a hybrid matrix amplifier array
AU7132998A (en) * 1997-04-24 1998-11-13 Ortho-Mcneil Corporation, Inc. Substituted pyrrolopyridines useful in the treatment of inflammatory diseases
AU7927498A (en) * 1997-08-05 1999-03-01 Pfizer Products Inc. 4-aminopyrrole(3,2-d) pyrimidines as neuropeptide y receptor antagonists
AU3117899A (en) 1998-04-02 1999-10-25 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
AU3210799A (en) * 1998-04-02 1999-10-25 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
EP1071423A1 (fr) 1998-04-02 2001-01-31 Merck & Co., Inc. Antagonistes de la gonadoliberine
CA2326143A1 (fr) 1998-04-02 1999-10-14 Merck & Co., Inc. Antagonistes de l'hormone liberant la gonadotropine (gnrh)
US6025366A (en) 1998-04-02 2000-02-15 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
CA2326184A1 (fr) 1998-04-02 1999-10-14 Merck & Co., Inc. Antagonistes de l'hormone liberant la gonadotropine (gnrh)
EP1077967B1 (fr) 1998-05-12 2002-12-04 Wyeth Acides biphenyl-oxo-acetiques utiles dans le traitement de l'insulinoresistance et de l'hyperglycemie
JP4549534B2 (ja) 1998-05-26 2010-09-22 中外製薬株式会社 複素環を有するインドール誘導体及びモノ又はジアザインドール誘導体
US6232320B1 (en) 1998-06-04 2001-05-15 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
CZ439199A3 (cs) * 1998-07-10 2000-07-12 Pfizer Products Inc. 4-Aminopyrrol(3^-d)pyrimidiny jako antagonisty receptoru neuropeptidu Y
PL347138A1 (en) * 1998-09-18 2002-03-25 Basf Ag 4-aminopyrrolopyrimidines as kinase inhibitors
DE69920756T2 (de) 1998-12-31 2005-10-13 Aventis Pharmaceuticals, Inc. Alpha-substituierung von ungeschützten beta-aminoestern
CA2375843A1 (fr) 1999-06-04 2000-12-14 Qi Zhao Compositions et methodes permettant d'inhiber la mort cellulaire
US6207699B1 (en) 1999-06-18 2001-03-27 Richard Brian Rothman Pharmaceutical combinations for treating obesity and food craving
PE20010306A1 (es) 1999-07-02 2001-03-29 Agouron Pharma Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa
US6387900B1 (en) 1999-08-12 2002-05-14 Pharmacia & Upjohn S.P.A. 3(5)-ureido-pyrazole derivatives process for their preparation and their use as antitumor agents
DE19944051A1 (de) 1999-09-14 2001-03-15 Wilke Heinrich Hewi Gmbh Verriegelungsvorrichtung
DE19951360A1 (de) 1999-10-26 2001-05-03 Aventis Pharma Gmbh Substituierte Indole
OA12514A (en) 1999-12-24 2006-05-29 Aventis Pharma Ltd Azaindoles.
YU54202A (sh) 2000-01-18 2006-01-16 Agouron Pharmaceuticals Inc. Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije
KR20030024659A (ko) 2000-02-17 2003-03-26 암겐 인코포레이티드 키나제 억제제
US6264966B1 (en) 2000-02-22 2001-07-24 Concat, Ltd. Compounds with chelation affinity and selectivity for first transition elements and their use in cosmetics and personal care products, inhibition of metalloenzymes, and inhibition of reperfusion injury
WO2001062252A1 (fr) 2000-02-25 2001-08-30 Merck & Co., Inc. Inhibiteurs de tyrosine-kinase
DE10009000A1 (de) 2000-02-25 2001-08-30 Basf Ag Verfahren zur Herstellung substituierter Indole
GB0007657D0 (en) 2000-03-29 2000-05-17 Celltech Therapeutics Ltd Chemical compounds
CA2398446A1 (fr) 2000-04-18 2001-10-25 Agouron Pharmaceuticals, Inc. Pyrazoles permettant d'inhiber des proteines kinases
WO2001082930A1 (fr) * 2000-05-03 2001-11-08 Tularik Inc. Agents microbiens a base de pyrazole
MXPA02010763A (es) 2000-06-14 2003-03-10 Warner Lambert Co Heterociclicos biciclos-6,5 fusionados.
US6407259B1 (en) 2000-07-28 2002-06-18 Pfizer Inc. Process for the preparation of pyrazoles
US6897231B2 (en) 2000-07-31 2005-05-24 Signal Pharmaceuticals, Inc. Indazole derivatives as JNK inhibitors and compositions and methods related thereto
CA2422354C (fr) 2000-09-15 2009-12-08 Vertex Pharmaceuticals Incorporated Composes pyrazoliques utiles comme inhibiteurs de la proteine kinase
GB0115109D0 (en) * 2001-06-21 2001-08-15 Aventis Pharma Ltd Chemical compounds

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0737685A1 (fr) * 1995-04-14 1996-10-16 Adir Et Compagnie Nouveaux composés pyridiniques, leurs procédés de préparation et les compositions pharmaceutiques qui les contiennent
WO1998022457A1 (fr) * 1996-11-19 1998-05-28 Amgen Inc. Agents anti-inflammatoires a base de pyrrole condense a substitution aryle et heteroaryle
WO1998047889A1 (fr) * 1997-04-23 1998-10-29 Novartis Ag Derives de chromane
WO1999020624A1 (fr) * 1997-10-20 1999-04-29 F.Hoffmann-La Roche Ag Inhibiteurs bicycliques d'une kinase

Also Published As

Publication number Publication date
CN1615873A (zh) 2005-05-18
OA12514A (en) 2006-05-29
BG106836A (bg) 2003-04-30
BG66066B1 (bg) 2011-01-31
WO2001047922A3 (fr) 2002-01-17
KR20020062663A (ko) 2002-07-26
HK1050191A1 (en) 2003-06-13
NO323766B1 (no) 2007-07-02
SK288019B6 (sk) 2012-11-05
AU777717B2 (en) 2004-10-28
CA2395593C (fr) 2011-08-02
CA2699568A1 (fr) 2001-07-05
CY1110951T1 (el) 2015-06-11
MA26857A1 (fr) 2004-12-20
CZ20022207A3 (cs) 2002-11-13
PL209572B1 (pl) 2011-09-30
EE05180B1 (et) 2009-06-15
NO20023032D0 (no) 2002-06-21
US20040198737A1 (en) 2004-10-07
BG66176B1 (bg) 2011-11-30
KR20070050103A (ko) 2007-05-14
BR0017038A (pt) 2003-01-07
EP1263759B1 (fr) 2010-09-08
CN1413213A (zh) 2003-04-23
JP5436507B2 (ja) 2014-03-05
NO20023032L (no) 2002-06-21
EA200200707A1 (ru) 2003-02-27
AP2006003492A0 (en) 2006-02-28
EA005212B1 (ru) 2004-12-30
BG110623A (bg) 2010-07-30
SK287882B6 (sk) 2012-02-03
AP2002002516A0 (en) 2002-06-30
IL150388A (en) 2010-11-30
IL193615A0 (en) 2009-05-04
HRP20020547B1 (en) 2011-06-30
SK9012002A3 (en) 2003-04-01
EP1990343A2 (fr) 2008-11-12
CZ301750B6 (cs) 2010-06-09
EP1990343A3 (fr) 2008-12-10
EE200200343A (et) 2003-06-16
CA2395593A1 (fr) 2001-07-05
US7227020B2 (en) 2007-06-05
HUP0203895A2 (hu) 2003-02-28
US20040009983A1 (en) 2004-01-15
KR100910488B1 (ko) 2009-08-04
WO2001047922A2 (fr) 2001-07-05
AU2209401A (en) 2001-07-09
EP1263759A2 (fr) 2002-12-11
HK1050191B (zh) 2011-04-29
KR100755622B1 (ko) 2007-09-04
CN100379734C (zh) 2008-04-09
PL355819A1 (en) 2004-05-17
NZ519121A (en) 2004-05-28
CA2699568C (fr) 2013-03-12
US6770643B2 (en) 2004-08-03
AP1587A (en) 2006-03-02
CZ301751B6 (cs) 2010-06-09
NO20066017L (no) 2002-06-21
EP1990343B1 (fr) 2012-04-04
IL150388A0 (en) 2002-12-01
HUP0203895A3 (en) 2004-09-28
JP2012031181A (ja) 2012-02-16
NO330747B1 (no) 2011-07-04
DZ3377A1 (fr) 2001-07-05
HRP20020547A2 (hr) 2005-10-31
MXPA02006338A (es) 2002-12-13

Similar Documents

Publication Publication Date Title
AP1917A (en) Azaindoles
DE60018571D1 (en) Hernienprothese
DE60008112D1 (en) Respiratorisches syncytialvirus replikation inhibitoren
DE50002490D1 (en) Polyester-polyetherblockcopolymere
DE60008382D1 (en) Respiratorisches syncytialvirus replikation inhibitoren
DE60018288D1 (en) Polyphenylensulfidlegierungszusammensetzung
DE60027722D1 (en) Aspartyl-protease inhibitoren
PL354600A1 (en) Naphthyridine derivatives
DE50002614D1 (en) Sigma-delta-modulator
DE60007505D1 (en) Propargyletherderivate
DE60011809D1 (en) Oxcarbazepinsuspension
DE50000137D1 (en) Spirofluorenopyrane
DE59909975D1 (en) Testleck
DE10081629D2 (en) Seilzugbefestigung
DE60001313D1 (en) Imidazodiazepinderivate
DE60012950D1 (en) Polyacetalharzzusammensetzung
DE50009469D1 (en) Common-rail-injektor
HUP0200274A2 (en) Fitting
GB9912283D0 (en) Bio-power
DE50010757D1 (en) Stilbenaufheller
DE60026282D1 (en) Photovervielfacherröhre
DE50012999D1 (en) Stirnwandisolation
EP1170018A4 (fr) Complexe lie par un ligand
DE60012212D1 (en) Orthotopisches totalkunstherz
DE60004080D1 (en) Centroidintegration